hepatotoxicity when using rifampin WITH pyrazinamide for latent tuberculosis

October 2001

There are new warnings about hepatotoxicity when using rifampin WITH pyrazinamide for latent tuberculosis.

Since the CDC recommended this combo last year, there have been 23 cases of hepatotoxicity...twice as many as with other TB regimens.

Now the CDC recommends patient evaluations every two weeks when using rifampin with pyrazinamide for latent TB...and to avoid the combo in patients with liver disease or previous isoniazid hepatotoxicity.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote